Pembrolizumab versus Ipilimumab in Advanced Melanoma
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
Publications
3 shownNivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who h...
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
A combination of dabrafenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic...
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 3
- Citations
- 12,680
- Institution
- Breast Cancer Research Foundation
External Links
Identifiers
- ORCID
- 0000-0003-2896-1957
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.